Trial · NCT02235311
Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed
NCT02235311, Not applicable, Terminated, University of Missouri-Columbia; results first posted 2017-07-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed. Trials, record NCT02235311. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02235311
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed
- NCT number
- NCT02235311
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 3 participants, actual
- Lead sponsor
- University of Missouri-Columbia
- Conditions
- Upper Gastrointestinal Bleed
- Interventions
- Pantoprazole
- First posted
- 2014-09-09
- Last updated
- 2017-07-31
- Results first posted
- 2017-07-02
- Limitations and caveats
- trial eliminated due to very low enrollment Poorly adopted by GI department due to fears of using once daily PPI despite available evidence Need for expansion to more sites for better enrollment
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ulcer Healing | 8 weeks | as defined by follow-up endoscopy per gastroenterology service, 8 weeks after UGIB acute management |
| Secondary | Rate of Rebleed | 8 weeks | Per patient report or as defined by follow-up endoscopy per gastroenterology service, 8 weeks after UGIB acute management High clinical suspicion of rebleed includes melena, hematochezia, confirmed by repeat endoscopy, requiring additional management |
| Secondary | Clostridium Difficile Diarrhea | 8 weeks | Clostridium difficile confirmed by polymerase chain reaction (PCR) |
| Secondary | Community-Acquired Pneumonia | 8 weeks | As defined by clinical suspicion and/or positive sputum culture requiring antibiotic treatment |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Ulcer Healing | 8 weeks | 1 ulcer located in duodenum, clean-base; randomized single-blinded to proton pump inhibitor (PPI) twice daily | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Rate of Rebleed | 8 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Clostridium Difficile Diarrhea | 8 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Community-Acquired Pneumonia | 8 weeks | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Ulcer Healing | Pantoprazole Twice Daily | 1 | Participants | ||
| Ulcer Healing | Pantoprazole Once Daily | 0 | Participants | ||
| Rate of Rebleed | Pantoprazole Twice Daily | 0 | Participants | ||
| Rate of Rebleed | Pantoprazole Once Daily | 0 | Participants | ||
| Clostridium Difficile Diarrhea | Pantoprazole Twice Daily | 0 | Participants | ||
| Clostridium Difficile Diarrhea | Pantoprazole Once Daily | 0 | Participants | ||
| Community-Acquired Pneumonia | Pantoprazole Twice Daily | 0 | Participants | ||
| Community-Acquired Pneumonia | Pantoprazole Once Daily | 0 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pantoprazole Twice Daily | 1 | |
| Overall Study | STARTED | Pantoprazole Once Daily | 2 | |
| Overall Study | COMPLETED | Pantoprazole Twice Daily | 1 | |
| Overall Study | COMPLETED | Pantoprazole Once Daily | 0 | |
| Overall Study | NOT COMPLETED | Pantoprazole Twice Daily | 0 | |
| Overall Study | NOT COMPLETED | Pantoprazole Once Daily | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pantoprazole Twice Daily | 0 | 1 |
| Total, all-cause mortality | Pantoprazole Once Daily | 0 | 0 |
| Total, other adverse events | Pantoprazole Twice Daily | 0 | 1 |
| Total, other adverse events | Pantoprazole Once Daily | 0 | 0 |
| Total, serious adverse events | Pantoprazole Twice Daily | 0 | 1 |
| Total, serious adverse events | Pantoprazole Once Daily | 0 | 0 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02235311
GET https://conductscience.org/api/trials/v1/NCT02235311/registered